| Airway obstruction in bronchial sarcoidosis: outcome with treatment. | |
| | |
MedLine Citation:
|
PMID: 10559075 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
STUDY OBJECTIVE: Airway obstruction (AO) in sarcoidosis is reported to be associated with respiratory symptoms, increased morbidity, and an increased mortality risk. Because AO in sarcoidosis may result from several causes, the therapeutic benefit of corticosteroids is difficult to determine. The aim of this study was to evaluate the therapeutic response of AO attributable to sarcoid granulomas in the bronchial wall. PATIENTS: We selected 11 patients who had sarcoidosis with AO (defined as FEV(1)/vital capacity [VC] < 70%) associated with sarcoid granulomas on an endobronchial biopsy. Exclusion criteria were history of asthma, smoker or ex-smoker, stage 4 disease, evidence of extrinsic compression by enlarged lymph nodes, and localized endobronchial stenosis seen during fiberoptic bronchoscopy. INTERVENTIONS: We compared the results of pulmonary function tests and clinical, radiologic, and biological findings at baseline with those obtained at the time of the last pulmonary function tests available, between the sixth and 12th months of treatment. Eight patients took oral corticosteroids (20 to 60 mg/d initially), one received IV methylprednisolone pulses, another took oral hydroxychloroquine, and the last one received IM methotrexate. Measurements and results: With treatment, FEV(1) and FEV(1)/VC significantly improved in eight patients (72%), normalized in four patients, and was unchanged in the remaining three patients. The mean FEV(1) increased from 60.8 +/- 10.8% to 76 +/- 13.7% of the predicted value (p < 0.02). VC did not change significantly. FEV(1)/VC increased from 76.1 +/- 6.4% to 87.6 +/- 10.7% of the predicted value (p < 0.01). Dyspnea on exertion and other clinical findings were attenuated in 10 patients; the chest radiograph improved in 9 patients, and normalized in 5 patients. The mean serum angiotensin-converting enzyme level decreased from 112 +/- 48 to 58 +/- 40 IU/mL (p < 0.05), and normalized in four patients. CONCLUSION: The present study indicates that AO caused by sarcoid granulomas in the bronchial wall can be either partially or completely reversed by treatment with a concomitant attenuation of pulmonary symptoms. |
| | |
Authors:
|
F Lavergne; C Clerici; D Sadoun; M Brauner; J P Battesti; D Valeyre |
Related Documents
:
|
18403045 - Predictors of talc pleurodesis outcome in patients with malignant pleural effusions. 19722355 - Characteristics of patients presenting with erythema nodosum and sarcoidosis. 17875065 - Clinical analysis of sarcoidosis presenting with heterochronic cardiac involvement. 20563815 - Erdheim-chester disease: ct findings of thoracic involvement. 16055695 - Pulmonary sequelae in convalescent patients after severe acute respiratory syndrome: ev... 952305 - Fluctuation of fetal hemoglobin in sickle-cell anemia. |
Publication Detail:
|
Type: Comparative Study; Journal Article |
Journal Detail:
|
Title: Chest Volume: 116 ISSN: 0012-3692 ISO Abbreviation: Chest Publication Date: 1999 Nov |
Date Detail:
|
Created Date: 1999-11-30 Completed Date: 1999-11-30 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0231335 Medline TA: Chest Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 1194-9 Citation Subset: AIM; IM |
Affiliation:
|
Service de Pneumologie, Hôpital Avicenne (Assistance Publique-Hôpitaux de Paris), UFR Bobigny, Bobigny, France. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Oral Adult Airway Obstruction / diagnosis, drug therapy*, etiology Antirheumatic Agents / administration & dosage, therapeutic use* Biopsy Bronchial Diseases / complications, diagnosis, drug therapy* Bronchoscopy Female Follow-Up Studies Glucocorticoids / administration & dosage, therapeutic use* Humans Hydroxychloroquine / administration & dosage, therapeutic use Male Methotrexate / administration & dosage, therapeutic use Methylprednisolone / administration & dosage, therapeutic use Middle Aged Radiography, Thoracic Respiratory Function Tests Retrospective Studies Sarcoidosis, Pulmonary / complications, diagnosis, drug therapy* Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Antirheumatic Agents; 0/Glucocorticoids; 118-42-3/Hydroxychloroquine; 59-05-2/Methotrexate; 83-43-2/Methylprednisolone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The incidence, prevalence, and severity of sarcoidosis in New York City firefighters.
Next Document: Physiological response to moderate exercise workloads in a pulmonary rehabilitation program in patie...